Lupin's subsidiary has signed a pact with Celnova Pharma to distribute NaMuscla in Argentina and Colombia. The drug treats non-dystrophic myotonic disorders, improving quality of life for patients. Celnova will handle registration, importation, storage, and sales, while Lupin will manufacture and supply the product.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.